Clinical Trial Update: Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab with gemcitabine in HER2-negative advanced breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Advanced Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-01-10